Across all ages, pCR rates were highest among patients with the tumor subtype HR– HER2+ , which affected 45.1% of patients compared with 34.0% and 30.4% of patients with the tumor subtypes HR– HER2– and HR+ HER2+ , respectively. This evidence concerns the gene ERBB2 and neoplasm.